Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200403712> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4200403712 endingPage "3661" @default.
- W4200403712 startingPage "3655" @default.
- W4200403712 abstract "Asenapine is a second-generation antipsychotic agent that is classified as a multi-acting receptor-targeted antipsychotic and is similar to olanzapine. Our study aimed to compare the treatment continuation rate and reason for discontinuation of asenapine or olanzapine in schizophrenia using real-world data.This design was a retrospective study. The primary endpoint was Kaplan-Meier estimates of the continuation rate at six months, with the propensity score method applied to adjust for potential confounders.A total of 95 patients were analyzed in this study (asenapine, n = 46; olanzapine, n = 49). Matched data were adjusted to consider six covariates (age, sex, chlorpromazine equivalent, diazepam equivalent, history of clozapine use, and history of modified electro convulsive therapy). The continuation rate at six months was 27.3% (95% CI, 15.6-47.6) in the asenapine group and 50.8% (95% CI, 34.3-75.3) in the olanzapine group (hazard ratio, 0.41; 95% CI, 0.21-0.82; P = 0.0088 by the Log rank test) in matched data. Cases of discontinuation because of the lack of efficacy were almost as frequent for asenapine (13.0%) as for olanzapine (10.2%). Discontinuation due to bitter taste (6.5%) and burden of the dosing method (6.5%) were observed only with asenapine, whereas anticholinergic side effects such as dry mouth (4.1%) and constipation (2.0%) were observed only with olanzapine.The low continuation rate of asenapine in real-world data may be related to specific factors such as bitter taste and burden of the dosing method." @default.
- W4200403712 created "2021-12-31" @default.
- W4200403712 creator A5008425814 @default.
- W4200403712 creator A5029952836 @default.
- W4200403712 creator A5079563814 @default.
- W4200403712 creator A5085641750 @default.
- W4200403712 date "2021-12-01" @default.
- W4200403712 modified "2023-09-28" @default.
- W4200403712 title "Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study" @default.
- W4200403712 cites W1538814565 @default.
- W4200403712 cites W1976358141 @default.
- W4200403712 cites W1981774197 @default.
- W4200403712 cites W1981820489 @default.
- W4200403712 cites W1987216800 @default.
- W4200403712 cites W2003289380 @default.
- W4200403712 cites W2052153499 @default.
- W4200403712 cites W2154849243 @default.
- W4200403712 cites W2411256025 @default.
- W4200403712 cites W2501657165 @default.
- W4200403712 cites W2765547688 @default.
- W4200403712 cites W2957311488 @default.
- W4200403712 cites W2998793403 @default.
- W4200403712 cites W3008183801 @default.
- W4200403712 cites W3090297822 @default.
- W4200403712 cites W3210868467 @default.
- W4200403712 cites W4287667740 @default.
- W4200403712 doi "https://doi.org/10.2147/ndt.s343840" @default.
- W4200403712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34934318" @default.
- W4200403712 hasPublicationYear "2021" @default.
- W4200403712 type Work @default.
- W4200403712 citedByCount "3" @default.
- W4200403712 countsByYear W42004037122022 @default.
- W4200403712 countsByYear W42004037122023 @default.
- W4200403712 crossrefType "journal-article" @default.
- W4200403712 hasAuthorship W4200403712A5008425814 @default.
- W4200403712 hasAuthorship W4200403712A5029952836 @default.
- W4200403712 hasAuthorship W4200403712A5079563814 @default.
- W4200403712 hasAuthorship W4200403712A5085641750 @default.
- W4200403712 hasBestOaLocation W42004037121 @default.
- W4200403712 hasConcept C118552586 @default.
- W4200403712 hasConcept C126322002 @default.
- W4200403712 hasConcept C2776412080 @default.
- W4200403712 hasConcept C2776619155 @default.
- W4200403712 hasConcept C2778715236 @default.
- W4200403712 hasConcept C2779626651 @default.
- W4200403712 hasConcept C2780494398 @default.
- W4200403712 hasConcept C2780864610 @default.
- W4200403712 hasConcept C71924100 @default.
- W4200403712 hasConceptScore W4200403712C118552586 @default.
- W4200403712 hasConceptScore W4200403712C126322002 @default.
- W4200403712 hasConceptScore W4200403712C2776412080 @default.
- W4200403712 hasConceptScore W4200403712C2776619155 @default.
- W4200403712 hasConceptScore W4200403712C2778715236 @default.
- W4200403712 hasConceptScore W4200403712C2779626651 @default.
- W4200403712 hasConceptScore W4200403712C2780494398 @default.
- W4200403712 hasConceptScore W4200403712C2780864610 @default.
- W4200403712 hasConceptScore W4200403712C71924100 @default.
- W4200403712 hasLocation W42004037121 @default.
- W4200403712 hasLocation W42004037122 @default.
- W4200403712 hasLocation W42004037123 @default.
- W4200403712 hasOpenAccess W4200403712 @default.
- W4200403712 hasPrimaryLocation W42004037121 @default.
- W4200403712 hasRelatedWork W1930398266 @default.
- W4200403712 hasRelatedWork W1996291403 @default.
- W4200403712 hasRelatedWork W2019652822 @default.
- W4200403712 hasRelatedWork W2025811041 @default.
- W4200403712 hasRelatedWork W2132144498 @default.
- W4200403712 hasRelatedWork W2143310966 @default.
- W4200403712 hasRelatedWork W2189233288 @default.
- W4200403712 hasRelatedWork W2400728488 @default.
- W4200403712 hasRelatedWork W3210140375 @default.
- W4200403712 hasRelatedWork W4386086458 @default.
- W4200403712 hasVolume "Volume 17" @default.
- W4200403712 isParatext "false" @default.
- W4200403712 isRetracted "false" @default.
- W4200403712 workType "article" @default.